A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer

被引：0

作者：

K. H. Park

S. Lee

J. H. Park

S. Y. Kang

H. Y. Kim

I. H. Park

Y. H. Park

Y. H. Im

H. J. Lee

S. Park

S.I. Lee

K.H. Jung

Y.S. Kim

Jae Hong Seo

机构：

[1] Korea University College of Medicine,Division of Oncology/Hematology, Department of Internal Medicine

[2] Severance Hospital,Division of Oncology, Department of Internal Medicine

[3] Yonsei University College of Medicine,Division of Oncology/Hematology, Department of Internal Medicine

[4] University of Ulsan College of Medicine,Department of Hematology

[5] Ajou University School of Medicine,Oncology

[6] Hallym University Sacred Heart Hospital,Division of Oncology/Hematology, Department of Internal Medicine

[7] National Cancer Center,Center for Breast Cancer and Center for Clinical Trials

[8] Samsung Medical Center,Division of Hematology/Oncology, Department of Internal Medicine

[9] Dong-A ST,Product Development HQ

[10] Seoul St. Mary’s Hospital,Division of Oncology, Department of Internal Medicine

[11] Catholic University College of Medicine,Division of Oncology/Hematology, Department of Internal Medicine

[12] Dong-A University College of Medicine,Department of Oncology, Asan Medical Center

[13] University of Ulsan College of Medicine,Division of Oncology/Hematology, Department of Internal Medicine

[14] Kosin University Gospel Hospital,undefined

来源：

Supportive Care in Cancer | 2017年 / 25卷

关键词：

Breast cancer; Pegylated G-CSF; TAC chemotherapy; Neutropenia;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：505 / 511

页数：6

共 208 条

[1]

Budman DR(1998)Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B J Natl Cancer Inst 90 1205-1211

[2]

Berry DA(1994)Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330 1253-1259

[3]

Cirrincione CT(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266

[4]

Henderson IC(2003)Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741 J Clin Oncol 21 1431-1439

[5]

Wood WC(2011)Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial J Clin Oncol 29 3877-3884

[6]

Weiss RB(2015)Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 33 3199-3212

[7]

Ferree CR(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 8-32

[8]

Muss HB(2003)Pharmacokinetics of pegfilgrastim Pharmacotherapy 23 9S-14S

[9]

Green MR(2010)Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18 529-541

[10]

Norton L(2013)A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer Investig New Drugs 31 1300-1306

← 1 2 3 4 5 6 7 8 9 10 →